NEW YORK (GenomeWeb News) – Finnish biotech firm Biohit today announced a distribution agreement with Hefei Medicine covering China.

The deal covers the distribution and marketing of Biohit's diagnostic products. Financial and other terms of the deal were not disclosed.

Among the products covered by today's announcement are Biohit's GastroPanel blood-based biomarker tests. The tests are for screening and diagnosing Helicobacter pylori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.